Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib

20251 citationsJournal Articlehybrid Open Access

Authors

Jean‐Claude Tardif · Montreal Heart Institute

Marc A. Pfeffer · Brigham and Women's Hospital

Simon Kouz · Cegep regional de Lanaudiere

Wolfgang Köenig · Universität Ulm

Aldo P. Maggioni · Associazione Nazionale Medici Cardiologi Ospedalieri

John J.V. McMurray · British Heart Foundation

David D. Waters

Abstract

Despite guideline directed therapy following ACS, history of prior coronary events and on-treatment LDL-C, A1c, hs-CRP and blood pressure remain determinants of future MI. In the Dal-GenE AA genotype patients, dalcetrapib reduced the rate of MI, independently of those variables. The Dal-GenE 2 trial is designed to confirm this pharmacogenetic hypothesis.

Topics & Keywords

Signaling Pathways in Disease Receptor Mechanisms and Signaling Protein Degradation and Inhibitors

Publication Details

Published in: European Journal of Preventive Cardiology

DOI: 10.1093/eurjpc/zwaf661

Field-Weighted Citation Impact: 0.81

Command Palette

Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib

Authors

Abstract

Topics & Keywords

Publication Details